Investment Portfolio
CarslMed: Individualized treatment plan for adult spinal deformity
- Project highlight: The world's first company that uses artificial intelligence and 3D printing technology to provide customized treatment plans for adult spinal deformities
- Investment stage: Seed round joint lead investment, continue to participate in Series A round
- Project update: Completed B round financing of $33M in 2022
Centerline biomedical: FDA Cleared Endovascular Therapy 3D Navigation Technology
- Project highlight: The world's first commercialized 3D navigation/GPS company for intraoperative management, providing physicians with a safe, real-time imaging solution that significantly improves clinical outcomes, lowers costs and reduces radiation time for patients and caregivers during surgery.
- Investment stage: Series B round
- Project
- Project highlight: The world's first commercialized 3D navigation/GPS company for intraoperative management, providing physicians with a safe, real-time imaging solution that significantly improves clinical outcomes, lowers costs and reduces radiation time for patients and caregivers during surgery.
- Investment stage: Series B round
- Project update: Completed B round financing of $30M, led by Cleveland clinic fund. The company's product has been used in many well-known hospitals such as Cleveland clinics, Allegheny general, university of Maryland medical center, university Virginia, etc.
Leo Cancer Care: Upright radiotherapy solution
- Project highlight: The world's first supplier of upright radiotherapy equipment with lower cost and fewer side effects on patients.
- Investment stage: Series B round
- Project update: July 2021, Leo Cancer Care raised $25.3m in Series B funding. Investors included Pureland Global Venture, Yu Galaxy, WARF, Alumni Ventures, Junson Capital and Se
- Project highlight: The world's first supplier of upright radiotherapy equipment with lower cost and fewer side effects on patients.
- Investment stage: Series B round
- Project update: July 2021, Leo Cancer Care raised $25.3m in Series B funding. Investors included Pureland Global Venture, Yu Galaxy, WARF, Alumni Ventures, Junson Capital and Serra Ventures as well as industry leaders CHC, Cosylab, Toret Devices and Radiation Business Solutions.
Smartlens: Convenient and affordable treatment for Glaucoma
- Project highlight: The first device capable of monitoring IOP as a non-invasive, easy to use, electronics-free, and low-cost solution giving doctors a better tool for Glaucoma management.
- Investment stage: Pre-A round
- Project update: Recently, Smartlens raised $3M for its Pre-A funding. Investors included Sophia Pharmaceuticals and Fund of Glaucoma Associates of Texas.
Hura Imaging: Diagnostic tool for early detection of ADRD
- Project highlight: First AI+ASL noninvasive diagnostic tool in the world for early detection of ADRD. Future Gold Standard for diagnosis of ADRD. Validated by 500+ AD and MCI cases (Breakthrough Device Program)
- Investment stage: Seed round
- Project update: The company has established commercial cooperation with five hospitals, including City
- Project highlight: First AI+ASL noninvasive diagnostic tool in the world for early detection of ADRD. Future Gold Standard for diagnosis of ADRD. Validated by 500+ AD and MCI cases (Breakthrough Device Program)
- Investment stage: Seed round
- Project update: The company has established commercial cooperation with five hospitals, including City of Hope and Hoag Hospital. It is planned to cooperate with more than 10 hospitals by the end of 2021.
Perceptive Medical: Blood pressure management system
- Project highlight: Using the world's first breakthrough technology to solve the problem of inefficient blood pressure management in the intensive care unit (ICU) and operating room.
- Investment stage: Seed round
- Project update: Completed seed round of financing and raised $1.15M for equipment design and prototype design.
iDENTICAL: 3D dental implant
- Project highlight: iDENTICAL shortens the patient's implantation and healing time through personalized, drill-free dental implants, and completely changes the experience of tooth replacement.
- Investment stage: Seed round
- Project update: Kicked-off the $15M Series A fundraising process in September 2021. Proceeds from the Series A will be us
- Project highlight: iDENTICAL shortens the patient's implantation and healing time through personalized, drill-free dental implants, and completely changes the experience of tooth replacement.
- Investment stage: Seed round
- Project update: Kicked-off the $15M Series A fundraising process in September 2021. Proceeds from the Series A will be used to support the pilot and pivotal clinical studies and 510(k) clearance.
Telesair: Respiratory care equipment for lung diseases
- Project highlight: Developed the market-leading next-generation respiratory care equipment that is safer and more efficient for use in clinics and homes.
- Investment stage: Seed round and A round
- Project update: Completed A round financing of $22M, including $3M from strategic investor Honeywell.
Cari Health: The first wearable device for monitoring opioid addiction
- Project highlight: The nation's first device for monitoring opioid addiction, one of the top ten important medical challenges in the United States, and the market is huge. The project was funded by NIH with $4M.
- Investment stage: Seed round
Eximius Diagnostics: Detection of early-stage liver cancer with nano-exosomes
- Project highlight: The company's products have made a breakthrough in the detection of early-stage liver cancer with nano-exosomes. The clinical trials of the products were carried out in UCLA medical center and Cedars-Sinal medical center, and the clinical effect was obvious. This project has received more than 20 million grants from NIH
- Project highlight: The company's products have made a breakthrough in the detection of early-stage liver cancer with nano-exosomes. The clinical trials of the products were carried out in UCLA medical center and Cedars-Sinal medical center, and the clinical effect was obvious. This project has received more than 20 million grants from NIH.
- Investment stage: Seed round
- Project update: The company just received BDD (breakthrough designation device) from FDA.
Paloma: The only female thyroid disease telemedicine platform in the U.S.
Lazzaro Medical: The first minimally invasive robotic device used in TBM repair surgery
- Project highlight: The number of potential female thyroid patients in the United States has reached 25 million, creating huge business opportunity for the platform. It has provided medical services to more than 20,000 people and the users are keep growing rapidly.
- Investment stage: Series A round
Lazzaro Medical: The first minimally invasive robotic device used in TBM repair surgery
Lazzaro Medical: The first minimally invasive robotic device used in TBM repair surgery
- Project highlight: The first American provider of robot-assisted, minimally invasive solutions for TBM (Tracheobronchomalacia) treatment.The company already had 150 successfully minimally invasive procedures with significant improvements in PF and SGRQ.FDA 510K clearance anticipated with commercial readiness Q1 2024.
- Investment stage: Pre-A round
Investment Portfolio
iDENTICAL: 3D dental implant
- Project highlight: iDENTICAL shortens the patient's implantation and healing time through personalized, drill-free dental implants, and completely changes the experience of tooth replacement.
- Investment stage: Seed round
- Project update: Kicked-off the $15M Series A fundraising process in September 2021. Proceeds from the Series A will be us
- Project highlight: iDENTICAL shortens the patient's implantation and healing time through personalized, drill-free dental implants, and completely changes the experience of tooth replacement.
- Investment stage: Seed round
- Project update: Kicked-off the $15M Series A fundraising process in September 2021. Proceeds from the Series A will be used to support the pilot and pivotal clinical studies and 510(k) clearance.
Eximius Diagnostics: Detection of early-stage liver cancer with nano-exosomes
- Project highlight: The company's products have made a breakthrough in the detection of early-stage liver cancer with nano-exosomes. The clinical trials of the products were carried out in UCLA medical center and Cedars-Sinal medical center, and the clinical effect was obvious. This project has received more than 20 million grants from NIH
- Project highlight: The company's products have made a breakthrough in the detection of early-stage liver cancer with nano-exosomes. The clinical trials of the products were carried out in UCLA medical center and Cedars-Sinal medical center, and the clinical effect was obvious. This project has received more than 20 million grants from NIH.
- Investment stage: Seed round
- Project update: The company just received BDD (breakthrough designation device) from FDA.
Modality.ai: Assessing neurological and psychiatric state
- Project highlight: The first automated, clinically validated, multimodal system to assess neurological and psychiatric states. The company has provided services to three of the top 10 pharmaceutical companies, and it recently signed a $2.8 million collaboration agreement with a biopharmaceutical company.
- Investment stage: Seed round
Neurava: Intelligent monitoring products for epilepsy and SUDEP risk
- Project highlight: The first U.S. company offering intelligent monitoring products for epilepsy and SUDEP risk, especially early warning for SUDEP risk. The company expects to get 510(k) clearance for arm wearable in Q4 2023, and 510(k) clearance for neck wearable in Q2 2024.
- Investment stage: Seed round
Bright Uro: Novel wireless,catheter-free urodynamic monitoring system
- Project highlight: Developing the urinary motility monitoring system/hardware and software with high level of comfortability, accuracy, and efficiency. The company’s patent is licensed from the Cleveland Clinic. The current urinary motility monitoring market is an insufficient market with low penetration rate, and there is huge room for d
- Project highlight: Developing the urinary motility monitoring system/hardware and software with high level of comfortability, accuracy, and efficiency. The company’s patent is licensed from the Cleveland Clinic. The current urinary motility monitoring market is an insufficient market with low penetration rate, and there is huge room for development. Laborie Medical Technologies, a leading global provider of urology diagnostic and therapeutic solutions, led Series A round of investment with $5M as a strategic investor.
- Investment stage: Series A round
3EO: Developing high-performing low-cost molecular diagnostics
- Project highlight: The first product on the market to provide high-precision point-of-care molecular testing at the price of an antigen test. Clinical trials show 99% accuracy, 95% PPA, and 100% NPA. The product has been approved by FDA for marketing. Strong market demand.
- Investment stage: Series A round
ImmeersiveTouch: A real time,hands-on surgical planning software via 3D/VR model
- Project highlight: A groundbreaking, FDA-510(k) cleared planning software that provides a real time,hands-on surgical planning experience using patient-specific anatomy. The company has obtained 4 FDA marketing approvals and European CE marketing approval. The product has been deployed in more than 40 hospitals, and till now there have be
- Project highlight: A groundbreaking, FDA-510(k) cleared planning software that provides a real time,hands-on surgical planning experience using patient-specific anatomy. The company has obtained 4 FDA marketing approvals and European CE marketing approval. The product has been deployed in more than 40 hospitals, and till now there have been 3,000 patient clinical cases.
- Investment stage: Bridge B round
iCardio.Ai: developing automated Ultrasound with artificial intelligence
- Project highlight: In 2024, the FDA granted Breakthrough Device Designation (BDD) to the company for its automatic detection of aortic stenosis. Established deep partnerships and revenue-sharing models with leading handheld ultrasound organizations worldwide (e.g., Butterfly Network, the largest handheld ultrasound company). Collaborating
- Project highlight: In 2024, the FDA granted Breakthrough Device Designation (BDD) to the company for its automatic detection of aortic stenosis. Established deep partnerships and revenue-sharing models with leading handheld ultrasound organizations worldwide (e.g., Butterfly Network, the largest handheld ultrasound company). Collaborating with Abbott to develop vascular ultrasound front-end AI products.
- Investment stage: Seed round
Aureka Biotechnologies: developing a best-in-class therapeutic discovery platform
- Project highlight: The company‘s platform utilizes generative AI + high-throughput digital biology to usher in a new era of data-driven innovative drug discovery. The company has developed a data-driven dry wet closed-loop intelligent drug discovery platform by combining its unique high-throughput single-cell functional screening (AuraLow
- Project highlight: The company‘s platform utilizes generative AI + high-throughput digital biology to usher in a new era of data-driven innovative drug discovery. The company has developed a data-driven dry wet closed-loop intelligent drug discovery platform by combining its unique high-throughput single-cell functional screening (AuraLowTM), synthetic biology-based protein hypermutation automatic evolution (AuraQuestTM), and protein language and structure-inspired generative AI big model (AuraPicassoTM).
- Investment stage: Seed round
Bloom Biomedical: minimally invasive interbody fusion implantation technology platform
- Project highlight: The First Minimally Invasive Interbody Fusion Implantation Technology Platform in the U.S. Market. The company has developed a balloon interbody fusion device, which is implanted using minimally invasive percutaneous surgery (MIS), with the catheter diameter being less than 5mm. MIS reduces postoperative pain and lowers
- Project highlight: The First Minimally Invasive Interbody Fusion Implantation Technology Platform in the U.S. Market. The company has developed a balloon interbody fusion device, which is implanted using minimally invasive percutaneous surgery (MIS), with the catheter diameter being less than 5mm. MIS reduces postoperative pain and lowers surgery-related complications. The procedure shortens surgery time by 30% to 70%, making it safer for patients and reducing hospital costs.
- Investment stage: Seed round
PiezoLabs Medical: vascular implant utilizing antithrombotic surface modification technology
PiezoLabs Medical: vascular implant utilizing antithrombotic surface modification technology
- Project highlight: Significant product efficacy: Patients implanted with stents can avoid taking dual antiplatelet drugs or significantly reduce the duration of dual antiplatelet therapy from 12 months to 3 months. Wide market applicability: This feature is broadly applicable to post-operative recovery in cardiovascular, cerebrovascular,
- Project highlight: Significant product efficacy: Patients implanted with stents can avoid taking dual antiplatelet drugs or significantly reduce the duration of dual antiplatelet therapy from 12 months to 3 months. Wide market applicability: This feature is broadly applicable to post-operative recovery in cardiovascular, cerebrovascular, and peripheral vascular implant surgeries, addressing common issues such as post-operative bleeding and thrombosis.
- Investment stage: Series A round
Show Less
Wearlinq: The first and only 6-lead wireless cardiac monitor
PiezoLabs Medical: vascular implant utilizing antithrombotic surface modification technology
- Project highlight: The First FDA-Approved Wearable 6-Lead EKG Patch in the U.S. Market. Compared with other single-lead wearable EKG patches, this product offers more accurate data transmission and more stable signals, making it highly favored by clinicians after its launch. The product's initial clinical application is in arrhythmia, wit
- Project highlight: The First FDA-Approved Wearable 6-Lead EKG Patch in the U.S. Market. Compared with other single-lead wearable EKG patches, this product offers more accurate data transmission and more stable signals, making it highly favored by clinicians after its launch. The product's initial clinical application is in arrhythmia, with future applications expected in sleep apnea, hypertension, and heart failure.
- Investment stage: Pre-A round
Vonova Inc.: Developing minimally invasive brain interface technologies
- Project highlight: Minimally Invasive Access: Utilizes the body's venous system as a natural pathway to the brain, eliminating the need for drilling through the skull. Real-Time Navigation: Employs advanced imaging techniques to guide the neurovascular system accurately, ensuring precise delivery of therapies. Interdisciplinary Expertise:
- Project highlight: Minimally Invasive Access: Utilizes the body's venous system as a natural pathway to the brain, eliminating the need for drilling through the skull. Real-Time Navigation: Employs advanced imaging techniques to guide the neurovascular system accurately, ensuring precise delivery of therapies. Interdisciplinary Expertise: Combines neuroscience and technology to create cutting-edge solutions for brain access.
- Investment stage: Seed round
Andromeda Surgical: The world’s first HoLEP + Mapping robotic platform for benign prostatic hyperplasia surgery.
- Leveraging proprietary nerve-sparing algorithms and automated laser control, the system reduces operative time and learning curve, lowers risks of erectile dysfunction / retrograde ejaculation, and fits within the existing CPT 52649 reimbursement pathway—positioning it to become the new standard of care in urodynamic surgery and high-volume HoLEP centers worldwide.
- Investment Stage:Series Seed
Early Diagnostics,Inc: Ultra-sensitive liquid biopsy technologies based on DNA methylation analysis for early cancer detection
- The company’s proprietary platform enables detection of rare tumor-derived methylation signals in blood at extremely early stages, offering a non-invasive, highly accurate solution with strong potential for population-scale cancer screening. Built on advanced bioinformatics and proprietary sample processing chemistry, the technology
- The company’s proprietary platform enables detection of rare tumor-derived methylation signals in blood at extremely early stages, offering a non-invasive, highly accurate solution with strong potential for population-scale cancer screening. Built on advanced bioinformatics and proprietary sample processing chemistry, the technology supports multi-cancer detection with minimal input DNA and is designed for cost-effective clinical deployment.
- Investment Stage:Series A
Toro Neurovascular: New standards in stroke care through innovative, catheter-based thrombectomy solutions.
Toro Neurovascular: New standards in stroke care through innovative, catheter-based thrombectomy solutions.
- Designed for broad global accessibility, Toro’s next-generation platform empowers physicians with intuitive, effective tools for removing blood clots during ischemic stroke — with a focus on improving patient outcomes in both high- and low-resource settings. By combining advanced catheter engineering with physician-centric design, Toro Ne
- Designed for broad global accessibility, Toro’s next-generation platform empowers physicians with intuitive, effective tools for removing blood clots during ischemic stroke — with a focus on improving patient outcomes in both high- and low-resource settings. By combining advanced catheter engineering with physician-centric design, Toro Neurovascular aims to make life-saving stroke interventions safer, faster, and more accessible worldwide.
- Investment Stage:Series Seed